Compare TWST & EFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TWST | EFC |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2018 | 2010 |
| Metric | TWST | EFC |
|---|---|---|
| Price | $29.62 | $13.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $46.33 | $14.46 |
| AVG Volume (30 Days) | ★ 1.9M | 1.5M |
| Earning Date | 11-14-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 11.46% |
| EPS Growth | N/A | ★ 1.22 |
| EPS | N/A | ★ 1.33 |
| Revenue | ★ $376,572,000.00 | $329,815,000.00 |
| Revenue This Year | $17.89 | N/A |
| Revenue Next Year | $16.81 | $8.81 |
| P/E Ratio | ★ N/A | $10.22 |
| Revenue Growth | ★ 20.32 | 13.84 |
| 52 Week Low | $23.30 | $11.12 |
| 52 Week High | $55.33 | $14.40 |
| Indicator | TWST | EFC |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 49.44 |
| Support Level | $25.67 | $13.30 |
| Resistance Level | $31.80 | $14.04 |
| Average True Range (ATR) | 1.96 | 0.20 |
| MACD | 0.25 | -0.02 |
| Stochastic Oscillator | 71.98 | 42.57 |
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.